MA-CONFORMATION-X-THER
Conformation-X Therapeutics, LLC, an immune-oncology focused drug development company, announced today that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M. The company unveiled its lead assets by disclosing successful ex vivo and in vivo proof-of-concept studies for its HHLA2 and IL18BP programs, marking critical milestones in the cancer drug development process.
Drawing inspiration from the fundamental role of protein conformations in disease biology and drug efficacy, Conformation-X applies unparalleled precision to developing novel immune checkpoint inhibitors. The company is creating a comprehensive portfolio of differentiated therapeutics addressing cancer mechanisms that have eluded existing treatments.
“The limitations of current checkpoint therapies are evident, as they don’t fully target the diverse spectrum of mechanisms associated with non-responsiveness and treatment resistance,” said Dr. Ali H. Munawar, CEO of Conformation-X Therapeutics.
Despite the pivotal role of PD-1/PD-L1 inhibitors in cancer immunotherapy, several peer-reviewed clinical studies have shown that the overall response rate across various cancers remains at or below 20%. Patients facing resistance to conventional checkpoint therapies encounter a range of challenges. This includes tumors that inherently possess low immunogenicity, are less likely to trigger an immune response, and immune exclusion, which restricts immune cells from the tumor microenvironment (TME). Moreover, complex genetic landscapes featuring oncogenic drivers and epigenetic modifications further contribute to immune evasion and influence treatment outcomes.
Dr. Munawar added, “We are committed to pioneering alternative therapeutic options for these patients by targeting novel biology and molecular pathways. The successive rounds of funding are a testament to our investors’ confidence in the innovation and rigor behind our efforts.”
The recent capital infusion accelerates the company towards translational studies of its lead asset and facilitates the expansion of its pipeline. The company's pipeline encompasses diverse drug target classes, extending beyond the current landscape of immune checkpoints to include novel soluble and epigenetic checkpoints while continuing to innovate within the B7-family of receptors.
“Achieving selective therapeutic targeting of HHLA2 demonstrates our team’s profound understanding of its intricate structure-function relationship and the critical role that HHLA2 plays in tumor immune evasion. Our work highlights the strength of Conformation-X’s drug discovery platform,” said Dr. Stephen Weeks, Sr. Director of Structural Biology and Biophysics.
About Conformation-X Therapeutics
Conformation-X utilizes a proprietary discovery platform enriched by structural insights to pioneer therapeutics with innovative mechanisms of action. The company is developing a diverse portfolio of immunotherapies that activate both the innate and adaptive arms of the immune system. The company’s premier preclinical asset includes a potent HHLA2-inhibitor that selectively restores its immune-suppressing effect with application in PD1/PDL1-negative cancers. To learn more visit www.conformationx.com.
Conformation-X Therapeutics is an independent, privately held research & development (R&D) company affiliated with the Pledge Therapeutics discovery platform.
About Pledge Therapeutics
Pledge Therapeutics is headquartered in Greater Boston with a second R&D branch in Leuven, Belgium. Pledge harnesses a state-of-the-art platform that merges structure-based drug design with biophysics, facilitating breakthroughs in the design of treatments for challenging therapeutic targets.
Pledge is grounded in a collaborative ethos, drawing on a network of experienced life sciences entrepreneurs, clinicians, and discovery scientists. Under its management umbrella, Pledge unites two independent biotech ventures: Orthogon Therapeutics, which specializes in antiviral treatments, and Conformation-X, dedicated to advancements in immune-oncology. This integrated model reinforces Pledge’s mission to revolutionize patient care across diverse therapeutic areas. More info on www.pledge-tx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403623298/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tigo Energy Drive Towards Total Quality Solar Pays off With 1,000-System Green Glove Milestone5.2.2025 15:00:00 CET | Press release
Tigo Green Glove milestone covers installations on four continents, delivering comprehensive support to Commercial & Industrial (C&I) customers, and is expanding for residential installers. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” “Company”), a leading provider of intelligent solar and energy software solutions, today announced solar installers across four continents have enrolled more than 1,000 systems in the Tigo Green Glove program. Designed by Tigo as one of the main pillars to deliver Total Quality Solar (TQS) through comprehensive support at every stage of solar system deployment, the Green Glove program has rapidly become a vital resource for solar installers, driving faster design and deployment, higher-quality installations, inbuilt first-responder safety, and improved system performance and reliability. While nearly 70% of Green Glove engagements have come from the C&I sector, providing proactive quality assurance in larger, more complex solar installations, Tigo is now acti
Global CIO Study Reveals ROI Remains Greatest AI Adoption Barrier, Despite Three-Fold Spend Increase5.2.2025 15:00:00 CET | Press release
Lenovo-commissioned research reveals forty-two percent of global organizations plan to institutionalize Generative AI use casesThirty-seven percent of management remains skeptical toward AI Business leaders and IT decision-makers confirm AI use will reach mainstream levels of adoption as organizations devote a greater slice of their IT budgets to AI implementations, according to new IDC research commissioned by Lenovo. The new global 2025 CIO Playbook entitled It’s Time for AI-nomics, highlights AI spending expectations by IT decision-makers globally to nearly triple in 2025 compared with last year. But critical challenges include uncertain financial returns on these investments and gaps in organizational readiness. Proving ROI: The Greatest Barrier While most AI use cases have met business expectations, proving the return of these investments remains challenging—financial risk and uncertain ROI rank as the greatest barriers to AI adoption. This tension is magnified by a disconnect bet
Datassential Expands Global Menu and Limited-Time Offer Data Across Europe’s Big 5 Markets5.2.2025 14:30:00 CET | Press release
Datassential, the leading food and beverage intelligence platform connecting the dots between consumers and the industry, has announced the expansion of its cutting-edge global sales intelligence solution to include in-depth menu and limited-time offer (LTO) tracking across Europe’s Big 5 markets: France, Germany, Italy, Spain, and the U.K. This enhancement further solidifies Datassential’s position as the gold standard for empowering the foodservice ecosystem with actionable insights. With a foodservice prospecting platform tracking more than 11 million operators across 70+ countries and 100+ operator attributes, Datassential’s solution offers unparalleled tools to increase sales productivity and win rates. The addition of comprehensive menu data in these key European markets gives users access to deep insights, enabling smarter, data-driven menu recommendations tailored to operators' diverse needs. “Understanding global menus and limited-time offers has never been more critical for o
Celonis Research Unveils: 89% of Business Leaders say AI Without Process Intelligence Fails to Deliver Expected Results5.2.2025 10:00:00 CET | Press release
The vast majority of decision makers surveyed (89%) said AI needs to have the context of how their business runs to deliver the expected results.81% of respondents said their companies plan to use AI specifically to improve business processes in the next 12 months.The majority (58%) of leaders worry that process shortcomings may limit AI’s contribution to their business. Celonis, the global leader in Process Mining and Process Intelligence, today released survey findings that demonstrate widespread recognition that AI requires Process Intelligence to be effective and relevant for the business. With Celonis Process Intelligence, AI gains the context it needs to understand how a business runs and how to make it run better. The 2025 Process Optimization Report shows that the vast majority of enterprise leaders (89%) say it’s crucial that AI has the context of how their business runs if it is going to deliver meaningful results and increase operational efficiency. The majority (58%) worry
Infobip Recognized as a Worldwide CPaaS Leader by IDC MarketScape for the Third Time5.2.2025 10:00:00 CET | Press release
Global cloud communications platform Infobip has been named as a Leader in the IDC MarketScape: Worldwide Communications Platform as a Service (CPaaS) 2025 Vendor Assessment. This is the third time that Infobip has been named a Leader in this report. According to the report, “Infobip is a key player in the CPaaS market with a global footprint and strong capabilities underpinned by its broad portfolio for enterprises as well as a carrier-grade service offering.” Courtney Munroe, Research Vice President, Worldwide Telecommunications Research at IDC, said:“Infobip has an agile organization structure and appetite for innovation to meet evolving enterprise requirements that stimulates continued expansion of its capabilities and global presence. The firm’s strong breadth and depth of services has enabled it to grow rapidly while maintaining a strong financial position.” Silvio Kutić, CEO at Infobip, said: “Over the last year, Infobip has continued to invest in innovative new services. For in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom